Today is

Department of

Pharmacology & Systems Physiology 

Photo of  Bruce Yacyshyn, MD

Bruce Yacyshyn, MD

Professor of Digestive Diseases

Education/Credentials
  • Bachelor's Degree: University of Alberta
  • Medical Degree: University of Alberta
  • Chief Intern : Edmonton General Hospital
  • Assistant Resident: University of Toronto, Toronto General Hospital
  • Assistant Resident: University of Toronto, Toronto General Hospital
  • Senior Resident: University of Toronto, Sunnybrook Medicine Centre
  • Clinical Fellowship: Washington University School of Medicine
  • Research Fellowship: Washington University School of Medicine

Board Certifications & Licenses
  • Missouri License 1986
  • Alberta License 1989
  • Ohio License 2001
  • British Columbia License 2006
  • Indiana License 2008
  • Diplomate in Internal Medicine American Board of Internal Medicine, 1986
  • Internal Medicine FRCPC, 1988
  • Gastroenterology FRCPC, 1989
  • Certificate of Special Competence, Gastroenterology RCPSC, 1989
  • Certification Alberta Medical Association, 1989
  • Fellow of the American College of Gastroenterology 2006
  • Fellow American Gastroenterological Association 2011
Contact Information
  • Medical Sciences Building, 7th Floor
  • 231 Albert Sabin Way
  • PO Box 670595, ML 0595
  • Cincinnati, Ohio 670595
  • Office 513-558-5244
  • Fax 513-558-1744
  • Email bruce.yacyshyn@uc.edu

Peer Reviewed Publications

Display All

Matthis, Andrea L; Zhang, Bin; Denson, Lee A; Yacyshyn, Bruce R; Aihara, Eitaro; Montrose, Marshall H 2016. Importance of the Evaluation of N-Acetyltransferase Enzyme Activity Prior to 5-Aminosalicylic Acid Medication for Ulcerative Colitis. Inflammatory bowel diseases, 22 8, 1793-802

Engevik, Melinda A; Engevik, Kristen A; Yacyshyn, Mary Beth; Wang, Jiang; Hassett, Daniel J; Darien, Benjamin; Yacyshyn, Bruce R; Worrell, Roger T 2015. Human Clostridium difficile infection: inhibition of NHE3 and microbiota profile. American journal of physiology. Gastrointestinal and liver physiology, 308 6, G497-509

Engevik, Melinda A; Yacyshyn, Mary Beth; Engevik, Kristen A; Wang, Jiang; Darien, Benjamin; Hassett, Daniel J; Yacyshyn, Bruce R; Worrell, Roger T 2015. Human Clostridium difficile infection: altered mucus production and composition. American journal of physiology. Gastrointestinal and liver physiology, 308 6, G510-24

Travis, Simon P L; Schnell, Dan; Feagan, Brian G; Abreu, Maria T; Altman, Douglas G; Hanauer, Stephen B; Krzeski, Piotr; Lichtenstein, Gary R; Marteau, Philippe R; Mary, Jean-Yves; Reinisch, Walter; Sands, Bruce E; Schnell, Patrick; Yacyshyn, Bruce R; Colombel, Jean-Frédéric; Bernhardt, Christian A; Sandborn, William J 2015. The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. Journal of Crohn's & colitis, 9 8, 607-16

Winter, Harland S; Krzeski, Piotr; Heyman, Melvin B; Ibarguen-Secchia, Eduardo; Iwanczak, Barbara; Kaczmarski, Maciej; Kierkus, Jaroslaw; Kola?ek, Sanja; Osuntokun, Bankole; Quiros, J Antonio; Shah, Manoj; Yacyshyn, Bruce; Dunnmon, Preston M 2014. High- and low-dose oral delayed-release mesalamine in children with mild-to-moderately active ulcerative colitis. Journal of pediatric gastroenterology and nutrition, 59 6, 767-72

Yacyshyn, Mary B; Reddy, Tara N; Plageman, Lauren R; Wu, Jiang; Hollar, Amy R; Yacyshyn, Bruce R 2014. Clostridium difficile recurrence is characterized by pro-inflammatory peripheral blood mononuclear cell (PBMC) phenotype. Journal of medical microbiology, 63 Pt 10, 1260-73

Yacyshyn, Bruce R 2008. Adhesion molecule therapeutics in IBD. Inflammatory bowel diseases, 14 Suppl 2 , S279-80

Mant, Michael J; Bain, Vincent G; Maguire, Conor G; Murland, Keith; Yacyshyn, Bruce R 2006. Prevalence of occult gastrointestinal bleeding in celiac disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 4 4, 451-4

Yacyshyn, B R; Schievella, A; Sewell, K L; Tami, J A 2005. Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1. Clinical and experimental immunology, 141 1, 141-7

Yacyshyn, Bruce R 2005. Antisense oligonucleotide treatment of inflammatory bowel diseases. Methods in molecular medicine, 106 , 295-305

Yacyshyn, Bruce R; Pilarski, Linda M 2003. Discussion on the safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology, 125 5, 1562; author reply 1

Bowen-Yacyshyn, Mary Beth; Bennett, C F; Nation, N; Rayner, D; Yacyshyn, B R 2002. Amelioration of chronic and spontaneous intestinal inflammation with an antisense oligonucleotide (ISIS 9125) to intracellular adhesion molecule-1 in the HLA-B27/beta2 microglobulin transgenic rat model. The Journal of pharmacology and experimental therapeutics, 302 3, 908-17

Yacyshyn, B R; Barish, C; Goff, J; Dalke, D; Gaspari, M; Yu, R; Tami, J; Dorr, F A; Sewell, K L 2002. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. Alimentary pharmacology & therapeutics, 16 10, 1761-70

Yacyshyn, B R; Chey, W Y; Goff, J; Salzberg, B; Baerg, R; Buchman, A L; Tami, J; Yu, R; Gibiansky, E; Shanahan, W R 2002. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut, 51 1, 30-6

Yacyshyn, B R; Thomson, A B R 2002. The clinical importance of proton pump inhibitor pharmacokinetics. Digestion, 66 2, 67-78

Yacyshyn, B R; Crooke, S T 2001. The concept and application of antisense oligonucleotides. Diseases of the colon and rectum, 44 9, 1241-3

Chang, Q; Soper, B D; Yacyshyn, B R; Tepperman, B L 2000. Alterations in protein kinase C isoforms in experimentally-induced colitis in the rat. Inflammation research : official journal of the European Histamine Research Society ... [et al.], 49 1, 27-35

Yacyshyn, B R; Thomson, A B 2000. Critical review of acid suppression in nonvariceal, acute, uppergastrointestinal bleeding. Digestive diseases (Basel, Switzerland), 18 3, 117-28

Marcusson, E G; Yacyshyn, B R; Shanahan, W R; Dean, N M 1999. Preclinical and clinical pharmacology of antisense oligonucleotides. Molecular biotechnology, 12 1, 1-11

Vaile, J H; Meddings, J B; Yacyshyn, B R; Russell, A S; Maksymowych, W P 1999. Bowel permeability and CD45RO expression on circulating CD20+ B cells in patients with ankylosing spondylitis and their relatives. The Journal of rheumatology, 26 1, 128-35

Yacyshyn, B R; Shanahan, W R 1999. Making sense of antisense. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 13 9, 745-51

Yacyshyn, B R 1998. New biotechnological therapies for Crohn's disease: where are we now? BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 10 4, 301-16

Yacyshyn, B R 1998. Drug treatment for Crohn's disease. Lancet, 352 9129, 743

Yacyshyn, B R; Bowen-Yacyshyn, M B; Jewell, L; Tami, J A; Bennett, C F; Kisner, D L; Shanahan, W R 1998. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology, 114 6, 1133-42

Yacyshyn, B R; Bowen-Yacyshyn, M B; Pilarski, L M 1996. Inhibition by rapamycin of P-glycoprotein 170-mediated export from normal lymphocytes. Scandinavian journal of immunology, 43 4, 449-55

Yacyshyn, B R; Meddings, J B 1995. CD45RO expression on circulating CD19+ B cells in Crohn's disease correlates with intestinal permeability. Gastroenterology, 108 1, 132-7

Pilarski, L M; Yacyshyn, B R; Lazarovits, A I 1994. Analysis of peripheral blood lymphocyte populations and immune function from children exposed to cyclosporine or to azathioprine in utero. Transplantation, 57 1, 133-44

Yacyshyn, B R; Lazarovits, A; Tsai, V; Matejko, K 1994. Crohn's disease, ulcerative colitis, and normal intestinal lymphocytes express integrins in dissimilar patterns. Gastroenterology, 107 5, 1364-71

Jensen, G S; Belch, A R; Mant, M J; Ruether, B A; Yacyshyn, B R; Pilarski, L M 1993. Expression of multiple beta 1 integrins on circulating monoclonal B cells in patients with multiple myeloma. American journal of hematology, 43 1, 29-36

Yacyshyn, B R 1993. Activated CD19+ B cell lamina propria lymphocytes in ulcerative colitis. Immunology and cell biology, 71 ( Pt 4) , 265-74

Yacyshyn, B R; Pilarski, L M 1993. Expression of CD45RO on circulating CD19+ B-cells in Crohn's disease. Gut, 34 12, 1698-704

Pilarski, L M; Yacyshyn, B R; Jensen, G S; Pruski, E; Pabst, H F 1991. Beta 1 integrin (CD29) expression on human postnatal T cell subsets defined by selective CD45 isoform expression. Journal of immunology (Baltimore, Md. : 1950), 147 3, 830-7